文献速递脊柱关节炎

古塞奇尤单抗治疗银屑病关节炎伴轴性受累患者的短期有效性:真实世界多中心队列研究结果

Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项前瞻性真实世界多中心队列研究纳入67例银屑病关节炎伴轴性受累提示特征的患者,接受古塞奇尤单抗治疗至少4个月。4个月后BASDAI、ASDAS和DAPSA均显著下降,52.2%患者达到BASDAI≤4,27例中70.3%骶髂关节MRI病变评分改善≥0.80,未记录危及生命的不良事件。

要点

  • 古塞奇尤单抗治疗4个月后BASDAI、ASDAS和DAPSA均显著降低,52.2%患者达到BASDAI≤4。
  • 27例患者中70.3%骶髂关节MRI病变评分改善≥0.80,与临床反应平行。
  • 17.9%患者报告轻微不良事件,主要为注射部位反应,未记录危及生命的不良事件。

核心结论

  • 古塞奇尤单抗在银屑病关节炎伴轴性受累提示特征患者中显示出短期有效性。
  • 作者认为,尽管需进一步研究,本多中心真实世界研究可能提示古塞奇尤单抗在此情境下的临床可用性。

研究设计与样本

  • 前瞻性真实世界多中心队列研究,2022年6月至2023年6月纳入银屑病关节炎伴轴性受累且接受古塞奇尤单抗治疗至少4个月的患者。

主要发现

  • 共67例患者,年龄53.4±11.2岁,男性占26.9%。
  • 治疗4个月后BASDAI、ASDAS和DAPSA均显著降低,ΔBASDAI为-2.11±0.43,52.2%患者达到BASDAI≤4。
  • 27例患者评估了骶髂关节MRI,70.3%患者骶髂关节病变评分改善≥0.80,与临床反应平行。
  • 未记录危及生命的不良事件,17.9%患者报告轻微不良事件,主要为注射部位反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the short-term effectiveness of guselkumab in patients with psoriatic arthritis (PsA) and suggestive features of axial involvement in a prospective 'real-life' multicentre cohort. METHODS: Between June 2022 and June 2023, PsA patients with axial involvement were evaluated if treated at least for 4 months with guselkumab. The effectiveness was evaluated by BASDAI, ASDAS, DAPSA, and achievement of BASDAI ≤ 4, also exploiting predictive factors. In a group of patients, MRI findings on sacroiliac joints were assessed before and after guselkumab administration. RESULTS: Sixty-seven patients with PsA and suggestive features of axial involvement (age 53.4 ± 11.2 years, male sex 26.9%) were treated with guselkumab. After 4 months, a significant reduction of BASDAI, ASDAS, and DAPSA was observed. A ΔBASDAI of -2.11 ± 0.43 was estimated assessing the mean difference values before and after guselkumab administration and 52.2% of patients reached a BASDAI ≤ 4. In 27 patients, MRI findings on sacroiliac joints were assessed before and after guselkumab administration. A reduction of 0.80 or larger in the sacroiliac joint lesion score was observed in the majority of patients (70.3%) based on MRI improvements, paralleling with the clinical response. No life-threatening side effects were recorded; 17.9% of patients reported minor adverse events mainly injection site reactions. CONCLUSIONS: The short-term effectiveness of guselkumab in patients with PsA and suggestive features of axial involvement were shown. Although further studies are needed, our multicentre 'real-life' study may suggest the clinical usability of guselkumab in this context.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ruscitti P, Pantano I, Cataldi G, et al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort. Rheumatology (Oxford). 2025. PMID: 38598432. doi:10.1093/rheumatology/keae220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。